{"url_path":"/sec/mtva/8-k/2026-05-18/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ** **Regulation FD Disclosures.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1638287/0001104659-26-063059-index.html","accession_number":"0001104659-26-063059","cik":"0001638287","ticker":"MTVA","issuer_name":"MetaVia Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1638287/0001104659-26-063059-index.html","primary_entity_key":"0001638287","primary_entity_name":"MetaVia Inc."},"word_count":277,"has_tables":true,"body_markdown":"**Item 7.01.** **Regulation FD Disclosures.**\n\nOn May 18, 2026, MetaVia Inc. (the “Company”) issued a press release announcing that three late-breaking abstracts highlighting its cardiometabolic assets, DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, and vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist, have been accepted for poster presentations at the American Diabetes Association’s (ADA) 2026 Scientific Sessions. The ADA will be held June 5-8, 2026 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference.\n\nInformation contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.\n\nThe information in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.\n\n​"}